Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells

A Corrigendum to this article was published on 07 November 2014

This article has been updated

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: The manufacturing process for PSC-based therapies.

Change history

  • 10 October 2014

    In the version of this article initially published, two author names were misspelled: the correct names are Cavagnaro, not Cavanagro; Feigal not Feigel. In addition, the name for the Health Insurance Portability and Accountability Act (HIPAA) was given as Health Insurance Portability and Privacy Act (HIPPA). The errors have been corrected in the HTML and PDF versions of the article.

References

  1. Yamanaka, S. Cell Stem Cell 10, 678–684 (2012).

    CAS  Article  Google Scholar 

  2. Rao, M.S. & Collins, F.S. Stem Cells Transl. Med. 1, 15–17 (2012).

    Article  Google Scholar 

  3. Sipp, D. & Turner, L. Science 338, 1296–1297 (2012).

    CAS  Article  Google Scholar 

  4. Allison, M. Nat. Biotechnol. 30, 304 (2012).

    CAS  Article  Google Scholar 

  5. Ahrlund-Richter, L. et al. Cell Stem Cell 4, 20–26 (2009).

    Article  Google Scholar 

  6. Carpenter, M.K. & Couture, L.A. Regen. Med. 5, 569–579 (2010).

    CAS  Article  Google Scholar 

  7. Bravery, C.A. et al. Cytotherapy 15, 9–19 (2013).

    Article  Google Scholar 

  8. Rawley, J. et al. BioProcess International 10, 16–22 (2012).

    Google Scholar 

  9. Clarke, D. Stanton J. Cytotherapy. 14, 1032–1040 (2012).

    CAS  Article  Google Scholar 

  10. Lomax, G.P., Hull, S.C., Lowenthal, J., Rao, M. & Isasi, R. Stem Cells Transl. Med. 2, 727–730 (2013).

    Article  Google Scholar 

  11. Lowenthal, J., Lipnick, S., Rao, M. & Hull, S.C. Stem Cells Trans. Med. 1, 409–421 (2012).

    Article  Google Scholar 

  12. Magnus, D. J. Law Med. Ethics 38, 267–276 (2010).

    Article  Google Scholar 

  13. Georgieva, B.P. & Love, J.M. Regen. Med. 5, 581–591 (2010).

    Article  Google Scholar 

  14. Rao, M.S. Stem Cell Res. Ther. 4, 98 (2013).

    PubMed  PubMed Central  Google Scholar 

  15. Obasogie, O.K. & Theung, H. Stanford Technology Law Review 16, 51–78 (2012).

    Google Scholar 

  16. Turner, M. et al. Cell Stem Cell 13, 382–384 (2013).

    CAS  Article  Google Scholar 

  17. http://www.fda.gov/internationalprograms/internationalcommunications/embassybriefings/ucm202888.htm

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mahendra Rao.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Andrews, P., Cavagnaro, J., Deans, R. et al. Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells. Nat Biotechnol 32, 724–726 (2014). https://doi.org/10.1038/nbt.2973

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2973

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing